

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM604128

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Midcap Financial Trust		10/15/2020	Corporation: MARYLAND
RECEIVING PARTY DATA			
Name:	Therapure Biopharma Inc.		
Street Address:	420 Ambassador Drive		
City:	Mississauga, Ontario		
State/Country:	CANADA		
Postal Code:	L5T 2J3		
Entity Type:	Corporation: CANADA		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	6050449	DAKANSUMIN	
Registration Number:	4381498	THERAPURE BIOPHARMA	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	612-915-9636		
Email:	jurzedowski@bitlaw.com		
Correspondent Name:	James Urzedowski		
Address Line 1:	225 South 6th Street		
Address Line 2:	Suite 1750		
Address Line 4:	Minneapolis, MINNESOTA 55402		
NAME OF SUBMITTER:	James Urzedowski		
SIGNATURE:	/James M. Urzedowski/		
DATE SIGNED:	10/21/2020		
Total Attachments: 6			
source=20-10-15-6166-Therapure-Biopharma-Release#page1.tif			
source=20-10-15-6166-Therapure-Biopharma-Release#page2.tif			
source=20-10-15-6166-Therapure-Biopharma-Release#page3.tif			
source=20-10-15-6166-Therapure-Biopharma-Release#page4.tif			

OP \$65.00 6050449

source=20-10-15-6166-Therapure-Biopharma-Release#page5.tif

source=20-10-15-6166-Therapure-Biopharma-Release#page6.tif

THERAPURE BIOPHARMA INC.

**RELEASE AND DISCHARGE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY**

RECITALS:

- A. Therapure Biopharma Inc. (“**Therapure**”) is the owner of: (i) the trademarks set forth in Exhibit A, the registrations and applications for the trademarks identified therein and the underlying goodwill of said trade marks (collectively, the “**Trademarks**”); and (ii) the patent applications and issued patents applications set forth in Exhibit A (collectively, the “**Patents**”, and together with the Trademarks, the “**Intellectual Property**”).
- B. Therapure entered into intellectual property security agreement dated as of November 20, 2015 in favour of Midcap Financial Trust, in its capacity as administrative agent (the “**Agent**”) (as amended, modified, supplemented or restated from time to time, the “**IP Security Agreement**”) under which Therapure granted to the Agent, a security interest in the Intellectual Property, as security for its obligations under a certain credit and security agreement.
- C. All of the obligations secured by the foregoing IP Security Agreement have been discharged and paid in full.
- D. The Agent has agreed to issue this document for the purposes of evidencing the foregoing and discharging all security interests registered against the Intellectual Property.

NOW THEREFORE for good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Agent hereby irrevocably and unconditionally releases and discharges to and in favour of Therapure and its successors and assigns each and every security interest, lien, mortgage, charge, pledge, assignment and other encumbrance (collectively, “**Liens**”) created under each and every mortgage, charge or security agreement made by Therapure in favour of the Agent over the Intellectual Property and the Agent hereby authorizes Therapure and its solicitors and agents to discharge all registrations of such Liens made against the Intellectual Property.

DATED at Bethesda, MD this 15th day of October, 2020.

MIDCAP FINANCIAL TRUST

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By: _____



Name: Maurice Amsellem
Title: Authorized Signatory

EXHIBIT A

**TRADE MARK APPLICATIONS AND/OR REGISTRATIONS
OWNED BY THERAPURE BIOPHARMA INC.**

Canada

Trademark	Application No.	Filing Date	Registration No.	Registration Date
DAKANSUMIN	1700384	10/30/2014	TMA1048713	08/13/2019
THERAPURE BIOLOGICS	1706644	12/10/2014	TMA1032968	06/27/2019
THERAPURE BIOLOGICS & Design	1706649	12/10/2014	TMA1031866	06/25/2019
THERAPURE BIOPHARMA	1404333	07/22/2008	TMA803323	08/02/2011
THERAPURE BIOPHARMA INC. & Design	1576076	05/02/2012	TMA849790	04/29/2013

United States

Trademark	Serial No.	Filing Date	Registration No.	Registration Date
DAKANSUMIN	86/607,617	10/30/2014	6050449	05/12/2020
THERAPURE BIOPHARMA	77547843	08/15/2008	4381498	08/13/2013

**PATENT APPLICATIONS AND/OR ISSUED PATENTS
OWNED BY THERAPURE BIOPHARMA INC.**

Canada

Title	Application No.	Filing Date	Patent No.	Issue Date
BLOOD CELL PRODUCTION VIA ACTIVATION OF THE HEMOGLOBIN SCAVENGER RECEPTOR	2,441,566	03/26/2002	2,441,566	02/22/2011
POLYSACCHARIDE-PROTEIN CONJUGATES REVERSIBLY COUPLED VIA IMINE BONDS	2,728,000	06/26/2009	2,728,000	04/17/2018
TARGETED DELIVERY OF ANTI-VIRAL COMPOUNDS THROUGH HEMOGLOBIN BIOCONJUGATION	2,566,874	05/17/2004	2,566,874	07/08/2014

United States

Title	Serial No.	Filing Date	Patent No.	Issue Date
BLOOD CELL PRODUCTION VIA ACTIVATION OF THE HEMOGLOBIN SCAVENGER RECEPTOR	10/471,604	09/24/2003	7,524,500	03/26/2009
ISOLATION OF HUMAN PLASMA OR SERUM PROTEINS	11/570,154	07/13/2007	9,624,260	04/18/2017
ISOLATION OF HUMAN PLASMA OR SERUM PROTEINS	14/688,906	04/16/2015	9,428,545	08/30/2016
POLYSACCHARIDE-PROTEIN CONJUGATES REVERSIBLY COUPLED VIA IMINE BONDS	12/999,076	12/15/2010	8,840,877	06/26/2009